9 Scopus citations


Allogeneic hematopoietic cell transplantation offers the best chance for cure in many hematologic malignancies. Key decisions include patient selection, donor and graft source, conditioning regimen, and graft-versus-host disease (GVHD) prophylaxis. Transplant is risky; only one-third survive long term. Complications include relapse, GVHD, infection, and end-organ dysfunction. Expanding indications for transplantation, advancing upper age limits, and improvements in patient care have resulted in increasing numbers of transplant survivors. These patients may suffer substantial long-term health consequences and require intensive follow-up. Future directions include graft engineering and cellular therapy, optimizing donor selection, sensitive disease assessments and/or maintenance therapies, and improvements in care.

Original languageEnglish
Pages (from-to)575-593
Number of pages19
JournalClinics in Chest Medicine
Issue number4
StatePublished - Dec 2017


  • Allogeneic hematopoietic cell transplantation
  • Complications
  • Graft-versus-host disease
  • Hematologic malignancies


Dive into the research topics of 'Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies'. Together they form a unique fingerprint.

Cite this